Upload
franklin-henderson
View
213
Download
0
Tags:
Embed Size (px)
Citation preview
Overview of Good Clinical Practices (GCPs)
Barbara Pennington, RN, MSPPD
2
Why Regulate Clinical Research?
Ensure the rights, safety, and well-being of participants
Scientific Integrity of data
3
Good Clinical Practices (GCPs)
Standards for designing, conducting, performing, monitoring, auditing, recording, analyzing, and reporting clinical trials.
4
GCP
FDA OHRP ICH
21 CFR 45 CFR 46 International• Electronic Docs. • Inf. Consent • $ Disclosure • IRBs • IND regs.
• IRBs • Inf. Consent•Women•Prisoners•Children
• glossary • principles• IRBs • Investigator • Sponsor • Essential Docs
5
U.S. FDA(Food and Drug Administration)
Branch of the United States Department of Health and Human ServicesRegulates all aspects of pharmaceutical industryTitle 21 of the Code of Federal Regulations (CFR)
6
CFR Title 21
Parts applicable to clinical research: Part 11 - Electronic Records and Signatures
Part 50 - Protection of Human Subjects
Part 54 - Financial Disclosure by Clinical Investigators
Part 56 - Institutional Review Boards
Part 312 - Investigational New Drug Application
Part 314 - Applications for FDA Approval to Market a New Drug or an Antibiotic Drug
Part 600 - Biological Products
Part 812 - Medical Devices
7
Form FDA 1572
Contract between FDA and InvestigatorLogistics such as names and addressesSection 9
Commitments of the Investigator
8
Investigator of Record (IOR) Agreement
For Non-IND studiesIdentifies key personnel, facilities, labs, IRBsAlso lists the commitments of the investigator
9
Commitments of the IOR
Comply with protocolEnsure compliance of IRB and consent process with 45CFR 46Report AEsAccurate record keeping and accessNo changes to study without permission of Sponsor and IRB
10
This is a Non-IND Study
Do we have to worry about FDA?
11
Office for Human Research Protections
(OHRP)OHRP responsible for ensuring the safety and welfare of people who participate in HHS sponsored researchUnder the DHHS Assistant Secretary of Health45 CFR part 46Formerly OPRR
12
45 CFR part 46
IRBInformed ConsentProtection of Fetuses, Pregnant Women Protection of PrisonersProtection of Children
13
45CFR 46 Subpart A
The “Common Rule”
Protection of Human SubjectsIRB/IECInformed Consent
Variations from FDA Regulations
14
45CFR 46 Subpart B
Protections for Pregnant Women, Fetuses and Neonates
DefinitionsRecent revisions
15
45CFR 46 Subpart C
Additional Protections for Prisoners involved in research
Definition of PrisonerAdditional IRB DutiesPermitted Research
16
45CFR 46 Subpart D
Additional Protections for Children involved in Research
AssentMinimal risks
International Conference on Harmonisation (ICH)
Guidelines for Good Clinical Practices
18
Objectives of ICH guidelines
Provide a unified standardEU; US; JapanTo facilitate mutual acceptance of clinical dataDeveloped in accordance with existing standards in US, EU, Japan, Australia, Canada, Nordic Countries, and WHO
19
ICH GCP Consolidated Guideline E6
Glossary Principles of ICH GCP Information regarding:
IRB/IEC Investigator Sponsor Protocol Investigator’s BrochureEssential Documents
20
Principles of ICH GCP
Conduct trials according to GCP Weigh risks vs. benefitsProtect the subjectsHave adequate information to justify trialWrite a sound protocolReceive IRB/IEC approvalUse qualified physicians
21
Principles of ICH GCP
Use qualified support staffObtain informed consentRecord information appropriatelyProtect confidentialityHandle investigational products appropriatelyImplement quality systems
22
Local Regulations
May have more detailed regulations that apply locallyDo not conflict with national regulations
23
Sponsor Policies
US Department of Health and Human Services
NIH/DAIT/DAIDSEssential Document and Source Document SOP
24
Internal SOPs
Standard Operating Procedures (SOPs)
Detailed instructions describing the what, when, where, and by whom of performing an activity
25
Compliance =
Adherence to GCPsSponsor policieslocal regulations
Investigator Responsibilities
27
Investigator Responsibilities*
Investigator Qualifications and Agreementsqualified by education, training and experiencefamiliar with protocol, IB, IPaware of and compliant with GCPs and applicable regspermit monitoring list of qualified personnel who are delegated duties
*(ICH 4.1-9)
SAMPLE
Delegation of Responsibility Log/Signature ListStudy:InvestigatorName
Site Number PageNumber
Name and Title of Site Staff Signature InitialsResponsibilities* Involved
FromInvolved To PI Initials
Use Block Capitals (See below) DD-MMM-YY DD-MMM-YY
A B C D E F G H I
A B C D E F G H I
A B C D E F G H I
A B C D E F G H I
A B C D E F G H I
A B C D E F G H I
A B C D E F G H I
DELEGATION OF RESPONSIBILITIES CODES NOTES FOR COMPLETING THIS FORM
A. Obtaining consentB. CRF entriesC. Dispensing MedicationD. Physical ExaminationE. PhlebotomyF. Essential Documents
G. IP Receipt/ReturnH. Query ResolutionI. Authorized Signatory forresolved queries
J. Other_____________
Please PRINT CLEARLY when completing this form Please enter all dates in the DD-MMM-YY format (e.g., 21-JAN-01) Use ‘Involved From’ and ‘Involved To’ to record staff changes during the study Enter a new line and applicable dates when responsibilities change PI should initial each line as individuals are assigned responsibilities
*Delete those which do not apply
Principal Investigator Signature (Close Out):_______________________________________ Date:_____________________________________
29
Investigator Responsibilities*
Adequate Resourcesrecruit adequate subjectssufficient timequalified staff and adequate facilities
Medical Care of Subjectsresponsible for all trial related medical decisions
*(ICH 4.1-4.9)
30
Investigator Responsibilities*
Communication with IRBapprovalsensure compliance
Compliance with ProtocolInvestigational Product (IP)
proper delegation of duties*(ICH 4.1-4.9)
31
How can the PI be held responsible for what the IRB does or does not do?
Document ALL interaction (verbal, electronic, written) with IRB including reminders of upcoming review requirements
32
Investigator Responsibilities*
Regulations require IRB is aware of changes in research activity
“…OHRP finds that changes to research protocol were implemented by investigators without IRB approval…”
33
Investigator Responsibilities*
Randomization & UnblindingInformed ConsentRecords and Reports
ensure accuracy, completeness, legibility and timeliness of datadata on CRF derived from Source Documentschanges made appropriatelyallow direct access
*(ICH 4.1-4.9)
34
Regulatory Authorities will
inquire about:Source of study subjectsDid they have the disease under studyDid they meet inclusion/exclusion criteriaWas the protocol precisely followed Were AEs reported appropriately
35
Common OHRP Findings
IRB failed to review the research at a convened meeting
failure to review grant applications
Investigators failed to promptly report unanticipated problems involving risks to subjects to IRB, OHRP and Sponsor
36
Common OHRP Findings
Continuing review of research was NOT substantive nor meaningful
include a summary of AEs and unanticipated problems# of subjects accruedsummary of recent literature, findings amendments, modifications since last reviewrelevant reports, information current consent form
37
Common OHRP Findings
IRB did not ensure additional protections for vulnerable subjectsIRB members with conflicting interest participated in reviewIRB meeting convened without Quorum (Non-scientist absent)
38
Common OHRP Findings
IRB review of NIH approved consent
any changes to the sample consent form related to risks or alternative procedures must be justified in writing by the investigator, approved by IRB and reflected in the IRB minutes
39
OHRP Finds that the IRB:
Lacks diversityis overburdened by large volumelevel of staff support is insufficientmembers lack detailed understanding of regs. for protection of human subjectsinadequate procedures for reporting of unanticipated problems
40
We Applaud COMPLIANCE
GCPs
Protocol
DAIT/DAIDS procedures
Local regulations